[1. ZAMAN A. Irritable bowel syndrome. Clin Cornerstone. 2002; 4:22-33.10.1016/S1098-3597(02)90003-7]Search in Google Scholar
[2. BRANDT LJ, CHEY WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl. 1:S1.10.1038/ajg.2009.134]Search in Google Scholar
[3. DROSSMAN DA, LI Z, ANDRUZZI E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.10.1007/BF01303162]Search in Google Scholar
[4. HAHN BA, SAUNDERS WB, MAIER WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997; 42:2585.10.1023/A:1018889318063]Search in Google Scholar
[5. SAITO YA, LOCKE GR, TALLEY NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816.10.1111/j.1572-0241.2000.03192.x]Search in Google Scholar
[6. TALLEY NJ, ZINSMEISTER AR, VAN DYKE C, MELTON LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927.10.1016/0016-5085(91)90717-Y]Search in Google Scholar
[7. THOMPSON WG, IRVINE EJ, PARE P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47:225.10.1023/A:1013208713670]Search in Google Scholar
[8. HUNGIN AP, WHORWELL PJ, TACK J, MEARIN F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment PharmacolTher 2003; 17:643.10.1046/j.1365-2036.2003.01456.x12641512]Search in Google Scholar
[9. DROSSMAN DA. Rome III: the new criteria. Chin J Dig Dis. 2006; 7(4):181-5.10.1111/j.1443-9573.2006.00265.x17054578]Search in Google Scholar
[10. DONALDSON RM, JR. Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med. 1964;270:1050-1056.10.1056/NEJM19640514270200714122803]Search in Google Scholar
[11. FORD AC, SPIEGEL BM, TALLEY NJ, MOAYYEDI P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. ClinGastroenterolHepatol.2009;7:1279-1286.10.1016/j.cgh.2009.06.03119602448]Search in Google Scholar
[12. BONFRATE L, TACK J, GRATTAGLIANO I, CUOMO R, PORTINCASA P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol.2013; 48(9):995-1009.10.3109/00365521.2013.79922023964766]Search in Google Scholar
[13. PYLERIS E, GIAMARELLOS-BOURBOULIS EJ, TZIAVRAS D, KOUSSOULAS V, BARBATZAS C, PIMENTEL M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci.2012; 57(5):1321-9.10.1007/s10620-012-2033-722262197]Search in Google Scholar
[14. SEKIROV I, RUSSELL SL, CAETANO M ANTUNES L, FINLAY BB. Gut microbiota in health and disease. Physiological Reviews.2010;90(3):859-904.10.1152/physrev.00045.200920664075]Search in Google Scholar
[15. PONNUSAMY K, CHOI JN, KIM J, LEE S-Y, LEE CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. Journal of Medical Microbiology 2011;60(6):817-827.10.1099/jmm.0.028126-0316792321330412]Search in Google Scholar
[16. KANG NL, OH YL. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.World J Gastroenterol. Jul 21, 2014; 20(27): 8886-8897.]Search in Google Scholar
[17. CARRARA M, DESIDERI S, AZZURRO M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. European Review for Medical and Pharmacological Sciences. 2008; 12(3):197-202.]Search in Google Scholar
[18. MALINEN E, RINTTILÄ T, KAJANDER K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. American Journal of Gastroenterology, 2005; 100(2):373-38.10.1111/j.1572-0241.2005.40312.x15667495]Search in Google Scholar
[19. CHOW J, LEE SM, SHEN Y, KHOSRAVI A, MAZMANIAN SK. Host-bacterial symbiosis in health and disease. Advances in Immunology.2010; 107(C):243-274.10.1016/B978-0-12-381300-8.00008-3315248821034976]Search in Google Scholar
[20. POSSERUD I, STOTZER PO, BJÖRNSSON ES, ABRAHAMSSON H, SIMRÉN M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007; 56(6):802-808.10.1136/gut.2006.108712195487317148502]Search in Google Scholar
[21. TOSKES PP. Bacterial overgrowth of the gastrointestinal tract. Adv Int Med. 1993; 38:387-407.]Search in Google Scholar
[22. VANNER S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut 2008; 57:1315-1321.10.1136/gut.2007.13362918250127]Search in Google Scholar
[23. GHOSHAL UC, SRIVASTAVA D, GHOSHAL U, MISRA A. Breath tests in the diagnosis of small intestinal bacterial over growth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J GastroenterolHepatol. 2014 Jul; 26(7):753-60.10.1097/MEG.000000000000012224849768]Search in Google Scholar
[24. NEWCOMER AD, MCGILL DB, THOMAS PJ, HOFMANN AF. Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med. 1975;293:1232-1236.10.1056/NEJM197512112932405]Search in Google Scholar
[25. URITA Y, ISHIHARA S, AKIMOTO T, KATO H, HARA N, HONDA Y, NAGAI Y, NAKANISHI K, SHIMADA N, SUGIMOTO M, et al. Seventy-five gram glucose tolerance test to assess carbohydrate malabsorption and small bowel bacterial overgrowth. World J Gastroenterol.2006; 12:3092-3095.10.3748/wjg.v12.i19.3092]Search in Google Scholar
[26. PERMAN JA, MODLER S, BARR RG, ROSENTHAL P. Fasting breath hydrogen concentration: normal values and clinical application. Gastroenterology. 1984; 87:1358-1363.10.1016/0016-5085(84)90204-X]Search in Google Scholar
[27. PIMENTEL M, CHOW EJ, LIN HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503-3506.10.1111/j.1572-0241.2000.03368.x]Search in Google Scholar
[28. GHOSHAL UC, GHOSHAL U, DAS K, MISRA A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006;25:6-10.]Search in Google Scholar
[29. BOND JH, LEVITT MD. Use of breath hydrogen (H2) to quantitate small bowel transit time following partial gastrectomy. J Lab Clin Med. 1977; 90:30-36.]Search in Google Scholar
[30. KING TS, ELIA M, HUNTER JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet.1998; 352:1187-1189.10.1016/S0140-6736(98)02146-1]Search in Google Scholar
[31. GHOSHAL UC. How to Interpret Hydrogen Breath Tests. Neurogastroenterol Motil. Jul 2011; 17(3): 312-317.10.5056/jnm.2011.17.3.312315506921860825]Search in Google Scholar
[32. PIMENTEL M, CHOW EJ, LIN HC. Normalization of lactulose breathtesting correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol.2003; 98:412-419.]Search in Google Scholar
[33. SCARPELLINI E1, GIORGIO V, GABRIELLI M, FILONI S, VITALE G, TORTORA A, OJETTI V, GIGANTE G, FUNDARÒ C, GASBARRINI A. Rifaximin treatment for small intestinalbacterialovergrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2013 May; 17(10):1314-20.]Search in Google Scholar
[34. YAKOOB J, ABBAS Z, KHAN R, HAMID S, AWAN S, JAFRI W. Small intestinal bacterial overgrowth and lactose intolerance contribute to irritable bowel syndrome symptomatology in Pakistan. Saudi J Gastroenterol. 2011; 17:371-375.10.4103/1319-3767.87176322110922064333]Search in Google Scholar
[35. MEYRAT P, SAFRONEEVA E, SCHOEPFER AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment PharmacolTher. 2012; 36:1084-1093.10.1111/apt.1208723066911]Search in Google Scholar
[36. LUPASCU A, GABRIELLI M, LAURITANO EC, SCARPELLINI E, SANTOLIQUIDO A, CAMMAROTA G, FLORE R, TONDI P, POLA P, GASBARRINI G, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005; 22:1157-1160.10.1111/j.1365-2036.2005.02690.x16305730]Search in Google Scholar
[37. REDDYMASU SC, SOSTARICH S, MCCALLUM EW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterol. 2010; 10:23.]Search in Google Scholar
[38. MORARU IG, MORARU AG, MIHAI A, CIORTESCU I, DRUG V, PORR P, VOIOSU R, IORDACHE T, DICULESCU M, PORTINCASA P, DUMITRASCU DL. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. Rom J Intern Med. 2014, 52 (4). .]Search in Google Scholar
[39. HUSEBYE E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy.2005; 51(suppl 1):1-22.10.1159/00008198815855746]Search in Google Scholar
[40. PISTIKI A, GALANI I, PYLERIS E, BARBATZAS C, PIMENTEL M, GIAMARELLOS-BOURBOULIS EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014 Jan 6.pii: S0924-8579(13)00412-3.]Search in Google Scholar
[41. MAGNUS S, GIOVANNI B, HARRY JF, BRENNAN MRS, ROBIN CS, STEPHEN V. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. Jan 2013; 62(1): 159-176. ]Search in Google Scholar